Pacific Biosciences Of California (PACB) Current Leases (2019 - 2026)

Pacific Biosciences Of California's Current Leases history runs 8 years deep, the most recent figure standing at $277000.0 for Q1 2026.

• On a quarterly basis, Current Leases fell 88.54% year-over-year to $277000.0 in Q1 2026; TTM through Mar 2026 was $277000.0, a 88.54% decrease from a year earlier, with the FY2025 full-year figure at $448000.0, down 95.53% from the prior year.
• Current Leases fell to $277000.0 in Q1 2026 per PACB's latest filing, from $448000.0 in the prior quarter.
• Across five years, Current Leases topped out at $12.5 million in Q2 2024 and bottomed at $277000.0 in Q1 2026.
• The 5-year median for Current Leases is $8.9 million (2022), against an average of $7.0 million.
• Across the five-year window, Current Leases soared 81.12% in 2022 and sank 95.53% in 2025, its largest moves.
• Year by year, Current Leases stood at $8.9 million in 2022, then advanced by 7.93% to $9.6 million in 2023, then increased by 4.54% to $10.0 million in 2024, then sank by 95.53% to $448000.0 in 2025, then plunged by 38.17% to $277000.0 in 2026.
• Per Business Quant, the three latest PACB Current Leases figures stand at $277000.0 (Q1 2026), $448000.0 (Q4 2025), and $621000.0 (Q3 2025).